Sousa Santos F, et al. - In this investigation, researchers outlined their experience with sorafenib and sunitinib in the treatment of radioactive iodine (RAI)-refractory metastatic differentiated thyroid cancer (DTC) and assessed and compared their effectiveness and adverse effect profiles. In total, 28 patients with RAI-refractory metastatic DTC were involved (26 had first-line treatment with sorafenib and 2 with sunitinib). Data reported that mean progression-free survival was 10.8 months with sorafenib and 6 months with sunitinib as a second-line treatment. It was noted that the best overall response was partial remission (PR) with either agent – PR rate of 30.7% with sorafenib and 37.5% with second-line sunitinib. All treatment courses had registered adverse effects and cessation of definitive treatment was justified by 13.9%. Findings suggested that sorafenib and sunitinib appear to be efficient therapy choices with an appropriate safety profile in delaying the development of disease in patients with RAI-refractory metastatic DTC. Interestingly, even in patients experiencing disease progression on sorafenib, sunitinib seems to show some efficacy.